Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript March 16, 2026 Kyntra Bio, Inc. beats earnings expectations. Reported EPS is $-3.61, expectations were $-3.885. Operator: Thank you for ...

Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio(NASDAQ:KYNB) reported that its rebranding, asset sale, and debt payoff have shifted the company’s financial structure and enabled a clinical focus on oncology and rare disease. Management ...
Becker's Spine Review

Robotics Isn’t a Spine Strategy: The Real Priorities for Building a Modern Spine Program

Over the past decade, robotic platforms have become one of the most visible symbols of innovation in spine surgery. Health ...
CURE

Keytruda Combo Extends Survival in Ovarian Cancer Trial: Expert Insights

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...
MarketWatch

C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity(TM) Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer's ...

C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation(R), has reached an agreement with BeauBrain Healthcare that brings its breakthrough ...
The American Journal of Managed Care

Managing Cardiometabolic Disease Is Key to Improving Health Outcomes in North Carolina

Cardiovascular disease is the leading cause of death in North Carolina, and effective management of the condition is essential to improving residents’ quality of life. Cardiovascular conditions are a ...
Targeted Oncology

Navigating Diagnostic Ambiguity and Histologic Uncertainty in HCC

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment. For oncology clinicians, the Liver Imaging-Reporting and Data System ...